{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:12:08Z","timestamp":1794316328981,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Buprenorphine is an effective first-line treatment for opioid use disorder (OUD) that substantially reduces morbidity and mortality. For patients using illicitly-manufactured fentanyl (IMF), however, transitioning to buprenorphine can be challenging. Evidence is lacking for how best to make this transition in the outpatient setting. A shared decision-making (SDM) approach has been found to benefit patients with OUD but has not been studied for buprenorphine initiation. We sought to explore participants\u2019 experiences with a SDM approach to buprenorphine initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were seeking care at a low barrier, telehealth buprenorphine clinic. Clinicians implemented a standardized SDM approach whereby they offered patients using IMF three options for buprenorphine initiation (traditional, low-dose, and QuickStart). They elicited patient goals and preferences and discussed the pros and cons of each method to come to a shared decision. Patients meeting study criteria were invited to participate in semi-structured qualitative interviews 1\u20132 weeks after the initial visit. Interviews focused on experiences with the clinical visit, suggestions for enhancing the treatment experience, and patient factors affecting the method they chose. Interviews were coded and analyzed using reflexive thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty participants completed interviews. Participants\u2019 mean age was 33, they were 50% female, predominantly white (16 [80%]), and most had Medicaid insurance (19 [95%]). We identified three important themes. First, participants found SDM acceptable and a positive addition to their OUD treatment. They felt their opinion mattered and reported that SDM gave them important control over their care plan. Second, patient goals, preferences, and past experiences with buprenorphine-associated withdrawal impacted what type of buprenorphine initiation method they chose. Finally, participants had advice for clinicians to improve SDM counseling. Participant recommendations included ensuring patients are informed that withdrawal (or \u201cfeeling sick\u201d) can occur with any initiation method, that buprenorphine will eventually \u201cblock\u201d fentanyl effects once at a high enough dose, and that clinicians provide specific advice for tapering off fentanyl during a low dose initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients with OUD using IMF, shared decision-making is an acceptable approach to buprenorphine initiation in the outpatient setting. It can enhance patient autonomy and lead to an individualized approach to OUD care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00555-0","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T23:04:19Z","timestamp":1741302259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["\u201cIt\u2019s within your own power\u201d: shared decision-making to support transitions to buprenorphine"],"prefix":"10.1186","volume":"20","author":[{"given":"Beth E.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason D.","family":"Andrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Dellabough-Gormley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley M.","family":"Buchheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"555_CR1","unstructured":"Medications for Opioid Use Disorder. Treatment improvement protocol (TIP) series 63 publication no. PEP21-02-01-002. Substance Abuse and Mental Health Services Administration; 2021."},{"issue":"6","key":"555_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","volume":"17","author":"MB Weimer","year":"2023","unstructured":"Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using High-potency synthetic opioids. J Addict Med. 2023;17(6):632\u20139.","journal-title":"J Addict Med"},{"issue":"4","key":"555_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","volume":"16","author":"KL Sue","year":"2022","unstructured":"Sue KL, Cohen S, Tilley J, Yocheved A. A Plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the Fentanyl era. J Addict Med. 2022;16(4):389\u201391.","journal-title":"J Addict Med"},{"key":"555_CR4","doi-asserted-by":"crossref","unstructured":"Wong S, Fabiano N, Webber D, Kleinman RA. High-dose buprenorphine initiation: a scoping review. J Addict Med. 2024;18(4):349\u201359.","DOI":"10.1097\/ADM.0000000000001296"},{"key":"555_CR5","doi-asserted-by":"publisher","first-page":"106740","DOI":"10.1016\/j.addbeh.2020.106740","volume":"114","author":"J Moe","year":"2021","unstructured":"Moe J, O\u2019Sullivan F, Hohl CM, Doyle-Waters MM, Ronsley C, Cho R, et al. Short communication: systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021;114:106740.","journal-title":"Addict Behav"},{"key":"555_CR6","doi-asserted-by":"publisher","unstructured":"Suen LW, Chiang AY, Jones BLH, et al. Outpatient low-dose initiation of buprenorphine for people using fentanyl. JAMA Netw Open. 2025;8(1):e2456253. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56253","DOI":"10.1001\/jamanetworkopen.2024.56253"},{"key":"555_CR7","unstructured":"Facher L. Fentanyl isn\u2019t just causing overdoses. It\u2019s making it harder to start addiction treatment. STAT. 2022 June 13, 2024. Available from: https:\/\/www.statnews.com\/2022\/11\/16\/fentanyl-isnt-just-causing-overdoses-its-making-it-harder-to-start-addiction-treatment\/"},{"key":"555_CR8","unstructured":"Why Are People Afraid of The Most Popular Opioid Addiction Treatment? 2024. Podcast. Available from:  https:\/\/tradeoffs.org\/2024\/01\/25\/fentanyl-opioid-addiction-transcript\/"},{"issue":"1","key":"555_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12954-024-00998-9","volume":"21","author":"BLH Jones","year":"2024","unstructured":"Jones BLH, Geier M, Neuhaus J, Coffin PO, Snyder HR, Soran CS, et al. Withdrawal during outpatient low dose buprenorphine initiation in people who use Fentanyl: a retrospective cohort study. Harm Reduct J. 2024;21(1):80.","journal-title":"Harm Reduct J"},{"key":"555_CR10","doi-asserted-by":"publisher","first-page":"1141980","DOI":"10.3389\/fpsyt.2023.1141980","volume":"14","author":"KE Dunn","year":"2023","unstructured":"Dunn KE, Bird HE, Bergeria CL, Ware OD, Strain EC, Huhn AS. Operational definition of precipitated opioid withdrawal. Front Psychiatry. 2023;14:1141980.","journal-title":"Front Psychiatry"},{"key":"555_CR11","doi-asserted-by":"crossref","unstructured":"Dunn KE, Strain EC. Establishing a research agenda for the study and assessment of opioid withdrawal. Lancet Psychiatry. 2024;11(7):566\u201372.","DOI":"10.1016\/S2215-0366(24)00068-3"},{"issue":"4","key":"555_CR12","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","volume":"16","author":"NB Varshneya","year":"2022","unstructured":"Varshneya NB, Thakrar AP, Hobelmann JG, Dunn KE, Huhn AS. Evidence of Buprenorphine-precipitated withdrawal in persons who use Fentanyl. J Addict Med. 2022;16(4):e265\u20138.","journal-title":"J Addict Med"},{"issue":"5","key":"555_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","volume":"17","author":"LA Grande","year":"2023","unstructured":"Grande LA, Cundiff D, Greenwald MK, Murray M, Wright TE, Martin SA. Evidence on buprenorphine dose limits: A review. J Addict Med. 2023;17(5):509\u201316.","journal-title":"J Addict Med"},{"key":"555_CR14","unstructured":"Center for Drug Evaluation and Research. FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder. U.S. Food and Drug Administration. December 26, 2024. Accessed December 27, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-recommends-changes-labeling-transmucosal-buprenorphine-products-indicated-treat-opioid-use"},{"issue":"2","key":"555_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bmjebm-2023-112289","volume":"29","author":"ML Clayman","year":"2024","unstructured":"Clayman ML, Scheibler F, R\u00fcffer JU, Wehkamp K, Geiger F. The six steps of SDM: linking theory to practice, measurement and implementation. BMJ Evidence-Based Med. 2024;29(2):75\u20138.","journal-title":"BMJ Evidence-Based Med"},{"key":"555_CR16","doi-asserted-by":"publisher","first-page":"108646","DOI":"10.1016\/j.jsat.2021.108646","volume":"135","author":"T Marshall","year":"2022","unstructured":"Marshall T, Hancock M, Kinnard EN, Olson K, Abba-Aji A, Rittenbach K, et al. Treatment options and shared decision-making in the treatment of opioid use disorder: A scoping review. J Subst Abuse Treat. 2022;135:108646.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"555_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bmjebm-2022-112068","volume":"28","author":"VM Montori","year":"2023","unstructured":"Montori VM, Ruissen MM, Hargraves IG, Brito JP, Kunneman M. Shared decision-making as a method of care. BMJ Evid Based Med. 2023;28(4):213\u20137.","journal-title":"BMJ Evid Based Med"},{"issue":"8","key":"555_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/acem.14507","volume":"29","author":"EM Schoenfeld","year":"2022","unstructured":"Schoenfeld EM, Westafer LM, Beck SA, Potee BG, Vysetty S, Simon C, et al. Just give them a choice: patients\u2019 perspectives on starting medications for opioid use disorder in the ED. Acad Emerg Med. 2022;29(8):928\u201343.","journal-title":"Acad Emerg Med"},{"issue":"2","key":"555_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/bmjebm-2023-112565","volume":"29","author":"M-A Durand","year":"2024","unstructured":"Durand M-A, Selby K, Okan Y. Visualisation of evidence for shared decision making. BMJ Evidence-Based Med. 2024;29(2):117\u201320.","journal-title":"BMJ Evidence-Based Med"},{"key":"555_CR20","doi-asserted-by":"publisher","first-page":"108444","DOI":"10.1016\/j.jsat.2021.108444","volume":"131","author":"BM Buchheit","year":"2021","unstructured":"Buchheit BM, Wheelock H, Lee A, Brandt K, Gregg J. Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects. J Subst Abuse Treat. 2021;131:108444.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"555_CR21","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1080\/08897077.2022.2060447","volume":"43","author":"R Lockard","year":"2022","unstructured":"Lockard R, Priest KC, Gregg J, Buchheit BM. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19. Subst Abus. 2022;43(1):1150\u20137.","journal-title":"Subst Abus"},{"issue":"4","key":"555_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajad.13135","volume":"30","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of Buprenorphine\/Naloxone: A review of the literature. Am J Addictions. 2021;30(4):305\u201315.","journal-title":"Am J Addictions"},{"issue":"2","key":"555_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/ADM.0000000000001073","volume":"17","author":"A Randall","year":"2023","unstructured":"Randall A, Hull I, Martin SA. Enhancing patient choice: using Self-administered intranasal Naloxone for novel rapid buprenorphine initiation. J Addict Med. 2023;17(2):237\u201340.","journal-title":"J Addict Med"},{"issue":"5","key":"555_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/ADM.0000000000000961","volume":"16","author":"LW Suen","year":"2022","unstructured":"Suen LW, Lee TG, Silva M, Walton P, Coffin PO, Geier M, et al. Rapid overlap initiation protocol using low dose buprenorphine for opioid use disorder treatment in an outpatient setting: A case series. J Addict Med. 2022;16(5):534\u201340.","journal-title":"J Addict Med"},{"issue":"2","key":"555_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qualitative Res Psychol"},{"issue":"9","key":"555_CR26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351.","journal-title":"Acad Med"},{"issue":"5","key":"555_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ADM.0b013e318297021e","volume":"7","author":"JJ Sanders","year":"2013","unstructured":"Sanders JJ, Roose RJ, Lubrano MC, Lucan SC. Meaning and methadone: patient perceptions of methadone dose and a model to promote adherence to maintenance treatment. J Addict Med. 2013;7(5):307\u201313.","journal-title":"J Addict Med"},{"issue":"10","key":"555_CR28","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","volume":"27","author":"G Elwyn","year":"2012","unstructured":"Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361\u20137.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"555_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/1049732311432718","volume":"22","author":"J Harris","year":"2012","unstructured":"Harris J, McElrath K. Methadone as social control: institutionalized stigma and the prospect of recovery. Qual Health Res. 2012;22(6):810\u201324.","journal-title":"Qual Health Res"},{"key":"555_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"555_CR31","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/10826080802483936","volume":"44","author":"S Anstice","year":"2009","unstructured":"Anstice S, Strike CJ, Brands B. Supervised methadone consumption: client issues and stigma. Subst Use Misuse. 2009;44(6):794\u2013808.","journal-title":"Subst Use Misuse"},{"issue":"7","key":"555_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.socscimed.2008.06.004","volume":"67","author":"P Radcliffe","year":"2008","unstructured":"Radcliffe P, Stevens A. Are drug treatment services only for \u2018thieving junkie scumbags\u2019? Drug users and the management of stigmatised identities. Soc Sci Med. 2008;67(7):1065\u201373.","journal-title":"Soc Sci Med"},{"issue":"1","key":"555_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/add.16646","volume":"120","author":"C Gregory","year":"2025","unstructured":"Gregory C, Yadav K, Linders J, Sikora L, Eagles D. Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review. Addiction. 2025;120(1):7\u201320.","journal-title":"Addiction"},{"issue":"6","key":"555_CR34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11606-016-3609-2","volume":"31","author":"AG Nathan","year":"2016","unstructured":"Nathan AG, Marshall IM, Cooper JM, Huang ES. Use of decision aids with minority patients: a systematic review. J Gen Intern Med. 2016;31(6):663\u201376.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"555_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0272989X10384739","volume":"31","author":"ME Peek","year":"2011","unstructured":"Peek ME, Tang H, Cargill A, Chin MH. Are there Racial differences in patients\u2019 shared decision-making preferences and behaviors among patients with diabetes? Med Decis Mak. 2011;31(3):422\u201331.","journal-title":"Med Decis Mak"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00555-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T10:42:26Z","timestamp":1741344146000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00555-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00555-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4595695\/v1","asserted-by":"object"}]},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was determined to be exempt human studies research and was approved by the Oregon Health and Science University Institutional Review Board (IRB #00025462).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study was approved for publication of deidentified research results by Oregon Health and Science University Institutional Review Board (IRB #00025462).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author Stephen A. Martin has the following disclosures: Boulder Care: Employment, stock options. Greylock Recovery: Employment. The remaining authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}